🇺🇸 NVA237 in United States

64 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Chronic Obstructive Pulmonary Disease — 33 reports (51.56%)
  2. Pneumonia — 13 reports (20.31%)
  3. Concomitant Disease Progression — 3 reports (4.69%)
  4. Cough — 3 reports (4.69%)
  5. Acute Myocardial Infarction — 2 reports (3.12%)
  6. Arterial Occlusive Disease — 2 reports (3.12%)
  7. Cardio-Respiratory Arrest — 2 reports (3.12%)
  8. Disease Progression — 2 reports (3.12%)
  9. Dyspnoea — 2 reports (3.12%)
  10. Hypertension — 2 reports (3.12%)

Source database →

NVA237 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is NVA237 approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for NVA237 in United States?

Novartis Pharmaceuticals is the originator. The local marketing authorisation holder may differ — check the official source linked above.